279 related articles for article (PubMed ID: 29268762)
21.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
22. Plasma ALU-247, ALU-115, and cfDNA Integrity as Diagnostic and Prognostic Biomarkers for Breast Cancer.
Hussein NA; Mohamed SN; Ahmed MA
Appl Biochem Biotechnol; 2019 Mar; 187(3):1028-1045. PubMed ID: 30151636
[TBL] [Abstract][Full Text] [Related]
23. Potential value of circulatory microRNA10b gene expression and its target E-cadherin as a prognostic and metastatic prediction marker for breast cancer.
Dwedar FI; Shams-Eldin RS; Nayer Mohamed S; Mohammed AF; Gomaa SH
J Clin Lab Anal; 2021 Aug; 35(8):e23887. PubMed ID: 34264524
[TBL] [Abstract][Full Text] [Related]
24. Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.
Panagopoulou M; Karaglani M; Balgkouranidou I; Biziota E; Koukaki T; Karamitrousis E; Nena E; Tsamardinos I; Kolios G; Lianidou E; Kakolyris S; Chatzaki E
Oncogene; 2019 May; 38(18):3387-3401. PubMed ID: 30643192
[TBL] [Abstract][Full Text] [Related]
25. Monitor tumor burden with circulating tumor DNA.
Figg WD; Reid J
Cancer Biol Ther; 2013 Aug; 14(8):697-8. PubMed ID: 23792566
[TBL] [Abstract][Full Text] [Related]
26. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
[TBL] [Abstract][Full Text] [Related]
27. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.
Daskalaki A; Agelaki S; Perraki M; Apostolaki S; Xenidis N; Stathopoulos E; Kontopodis E; Hatzidaki D; Mavroudis D; Georgoulias V
Br J Cancer; 2009 Aug; 101(4):589-97. PubMed ID: 19623181
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation and breast cancer: A way forward (Review).
Vietri MT; D'Elia G; Benincasa G; Ferraro G; Caliendo G; Nicoletti GF; Napoli C
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34726251
[TBL] [Abstract][Full Text] [Related]
29. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.
Chen Z; Feng J; Buzin CH; Liu Q; Weiss L; Kernstine K; Somlo G; Sommer SS
PLoS One; 2009 Sep; 4(9):e7220. PubMed ID: 19789704
[TBL] [Abstract][Full Text] [Related]
30. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
31. Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer.
Fernandez-Garcia D; Hills A; Page K; Hastings RK; Toghill B; Goddard KS; Ion C; Ogle O; Boydell AR; Gleason K; Rutherford M; Lim A; Guttery DS; Coombes RC; Shaw JA
Breast Cancer Res; 2019 Dec; 21(1):149. PubMed ID: 31856868
[TBL] [Abstract][Full Text] [Related]
32. Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer.
Magbanua MJM; Yau C; Wolf DM; Lee JS; Chattopadhyay A; Scott JH; Bowlby-Yoder E; Hwang ES; Alvarado M; Ewing CA; Delson AL; Van't Veer LJ; Esserman L; Park JW
Clin Cancer Res; 2019 Sep; 25(17):5388-5397. PubMed ID: 31142502
[TBL] [Abstract][Full Text] [Related]
33. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
[TBL] [Abstract][Full Text] [Related]
34. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
[TBL] [Abstract][Full Text] [Related]
35. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
[TBL] [Abstract][Full Text] [Related]
36. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
38. Transcripts of circulating tumor cells detected by a breast cancer-specific platform correlate with clinical stage in bladder cancer patients.
Todenhöfer T; Hennenlotter J; Dorner N; Kühs U; Aufderklamm S; Rausch S; Bier S; Mischinger J; Schellbach D; Hauch S; Feniuk N; Bedke J; Gakis G; Stenzl A; Schwentner C
J Cancer Res Clin Oncol; 2016 May; 142(5):1013-20. PubMed ID: 26910601
[TBL] [Abstract][Full Text] [Related]
39. PUM1 and RNase P genes as potential cell-free DNA markers in breast cancer.
Murillo Carrasco A; Acosta O; Ponce J; Cotrina J; Aguilar A; Araujo J; Rebaza P; Pinto JA; Fujita R; Buleje J
J Clin Lab Anal; 2021 Apr; 35(4):e23720. PubMed ID: 33522650
[TBL] [Abstract][Full Text] [Related]
40. Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis.
Ramirez AB; Bhat R; Sahay D; De Angelis C; Thangavel H; Hedayatpour S; Dobrolecki LE; Nardone A; Giuliano M; Nagi C; Rimawi M; Osborne CK; Lewis MT; Stilwell JL; Kaldjian EP; Schiff R; Trivedi MV
BMC Cancer; 2019 Mar; 19(1):220. PubMed ID: 30871481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
